Key Highlights

  • Third quarter Revenue rose 5.4% to USD 108.4 billion, topping the USD 104.8 billion estimate.
  • Adjusted Operating Income climbed 21% to USD 4.19 billion, and GAAP EPS was USD 1.68.
  • The medical benefit ratio improved to 91.3% from 92.8%, lifting Health Care Benefits income to USD 912 million.
  • Nine month Operating Cash Flow doubled to USD 15.3 billion, while long-term Debt fell to USD 57.2 billion.

CVS Health (NYSE:CVS) reported third quarter revenue of USD 108,399 million, up 5.4% from USD 102,871 million a year earlier and above the USD 104.8 billion estimate. Net Income attributable to the company was USD 2,172 million, or USD 1.68 per diluted share, compared with a loss of USD 3,975 million, or USD 3.13 per share, a year ago. The prior-year quarter included a USD 5,725 million Goodwill impairment.

Segment Results and Insurance Margins

Growth came mainly from Health Services and Health Care Benefits. Health Services revenue rose to USD 53,964 million from USD 49,266 million, and Health Care Benefits revenue increased to USD 36,855 million from USD 35,993 million. Pharmacy and Consumer Wellness revenue slipped to USD 35,498 million from USD 36,214 million. Consolidated product revenue rose to USD 69,225 million, and premiums reached USD 34,566 million.

The insurance Business recovered most visibly. Health Care Benefits adjusted operating income was USD 912 million against USD 314 million, as the medical benefit ratio improved 150 basis points to 91.3%, mainly on better underlying performance in the Government business. Health Services adjusted operating income edged up to USD 2,106 million from USD 2,050 million, and Pharmacy and Consumer Wellness rose to USD 1,635 million from USD 1,478 million. Corporate and other posted a loss of USD 459 million.

Earnings, Cash Flow and Balance Sheet

Consolidated adjusted operating income was USD 4,194 million versus USD 3,459 million. GAAP operating income was USD 3,566 million, after USD 425 million of intangible amortization and a USD 193 million contingent guarantee Liability tied to agreements related to Omnicare. Interest expense was USD 747 million, down from USD 784 million, and the income tax provision was USD 678 million.

Nine month operating cash flow reached USD 15,318 million against USD 7,249 million, and nine month operating income was USD 12,949 million versus USD 2,548 million. Cash and equivalents rose to USD 11,738 million from USD 8,453 million at year end, while long-term debt declined to USD 57,223 million from USD 60,502 million. The nine month medical benefit ratio was 87.8% compared with 90.0%, partly because premium deficiency reserves recorded in the prior year did not recur.

Disclosures and Risk Factors

CVS Health's disclosures describe legal matters it cannot estimate, including proceedings tied to the Omnicare guarantee, and note that Tariff refunds received in 2026 under the International Emergency Economic Powers Act were not material to results. The company also reports adjusted operating income by segment, defined to exclude intangible amortization, net realized capital gains and items outside the ordinary course of business.

Selling and administrative costs were steady. Operating expenses rose only slightly to USD 11,332 million from USD 11,288 million, which the company tied to continued business investments and the guarantee liability.

Figures Worth Comparing

Third quarter adjusted operating income of USD 4,194 million compares with USD 14,501 million for nine months, while the 91.3% medical benefit ratio sits against 87.8% for the first nine months. Cash of USD 11,738 million compares with long-term debt of USD 57,223 million. Revenue of USD 108,399 million compares with USD 314,921 million over nine months, up 6.3% from USD 296,374 million.